ACS Medicinal Chemistry Letters
Page 6 of 7
evaluation of oxamniquine methacrylate and acrylamide prodrugs.
Bioorg Med Chem, 2007, 15, 1229ꢀ1236.
matobium (S. h.) and S. japonicum (S. j.), S. mansoni sulfotransꢀ
ferase, SmSULTꢀOR, ND; not determined.
1
2
3
4
5
6
7
8
(19) Filho, S. B.; Gargioni, C.; Silva Pinto, P. L.; Chiodelli, S. G.;
Gurgel Vellosa, S. A.; Silva, R. M. da, et al. Synthesis and evaluation
of new oxamniquine derivatives, Int J Pharm. 2002, 233, 35ꢀ41.
(20) Sadhu, P.S.; Kumar, S. N.; Chandrasekharam, M.; Picaꢀ
Mattoccia, L.; Cioli, D.; Rao, V. J., Synthesis of new praziquantel
analogues: Potential candidates for the treatment of schistosomiasis,
P. S. Bioorg. Med. Chem. Lett. 2012, 22, 1103–1106.
(21) Kumar, S. N.; Sadhu, P.S.; Sharma, K. K.; PicaꢀMattoccia, L.;
Basso, A.; Cioli, D.; Rao, V. J Synthesis and antischistosomal activity
of new furoxan derivatives of praziquantel . Indian J. Chem., SEC B,
2017, 56B, 112ꢀ119.
(22) Hess, J.; Panic, G.; Patra, M.; Mastrobuoni, L.; Spingler, B.;
Roy, S.; Keiser, J.; Gasser, G. ACS Infect. Dis. 2017, 3, 645−652.
(23) Straathof, A. J. J.; Adlercreutz, P., Applied Biocatalysis, CRC
Press, ISBN 9780203305638, September 2, 2003.
(24) Boehm, D.; R.N.; Pryce, D. J., Schistosoma haematobium. N
Engl J Med, 2001, 344, 1170.
(25) Lu, J. J.; Crimin, K.; Goodwin, J. T.; Crivori, P.; Orrenius, C.;
Xing, L.; Tandler, P. J.; Vidmar, T. J.; Amore, B. M.; Wilson, A. G.
E.; Stouten, P. F. W.; Burton, P. S. Influence of Molecular Flexibility
and Polar Surface Area Metrics on Oral Bioavailability in the Rat. J.
Med. Chem. 2004, 47, 6104ꢀ6107.
(26) Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J.
Experimental and computational approaches to estimate solubility and
permeability in drug discovery and development settings. Adv. Drug.
Deliv. Rev. 2001, 46, 3ꢀ26.
(27) Ackermann, J.; Bleicher, K.; Chomienne, O.; Mattei, P.;
Sander, l. O. Novel Bicyclic Sulfonamide Derivativies Which Are Lꢀ
CPT1 inhibitors. 2007, US20100130484A1.
(28) Csatayova, K.; Davies, S. G.; Lee, J. A.; Kenneth B. Ling;
Roberts, P. M.; Russell, A. J.; Thomson, J. E. Syntheses of transꢀ
SCHꢀA and cisꢀSCHꢀA via a Stereodivergent Cyclopropanation Proꢀ
tocol. Org. Lett. 2010, 12, 3152ꢀ3155.
REFERENCES
(1) King, C. H.; Dickman, K.; Tisch, D. J. Reassessment of the cost
of chronic helmintic infection: a metaꢀanalysis of disabilityꢀrelated
outcomes in endemic schistosomiasis. Lancet. 2005, 365, 1561ꢀ1569.
(2) Doenhoff, M. J.; Cioli, D.; Utzinger, J. Praziquantel : mechaꢀ
nisms of action, resistance and new derivatives for schistosomiasis,
Current Opinions in Infectious Diseases. 2008, 21, 659ꢀ667.
(3) Cioli, D.; PicaꢀMattoccia, L.; Archer, S., AntiSchistosomal
Drugs: Past, Present... and Future? Pharmac. Ther. 1995, 68, 35ꢀ85.
(4) Foster, R.; Cheetham, B. L. Studies with the schistosomicide
oxamniquine (UKꢀ4271) I. Activity in rodents and in vitro, Trans. R.
Soc. Trop. Med. Hyg. 1973, 67, 674ꢀ684.
(5) Valentim, C. L. L.; Cioli, D.; Chevalier, F. D.; Cao, X. H.; Tayꢀ
lor, A. B.; et al. Genetic and molecular basis of drug resistance and
speciesꢀspecific drug action in schistosome parasites. Science 2013,
342, 1385ꢀ1389.
(6) Taylor, A. B.; Roberts, K. M.; Cao, X.; Clark, N. E.; Holloway,
S. P.; Donati, E.; Polcaro, C. M.; PicaꢀMattoccia, L.; Tarpley, R. S.;
McHardy, S. F.; Cioli, D.; LoVerde, P. T.; Fitzpatrick, P. F.; Hart, P.
J., Structural and enzymatic insights into speciesꢀspecific resistance to
schistosome parasite drug therapy. J. Biol. Chem. 2017, 292, 11154ꢀ
11164.
(7) Greenberg, R. M., New approaches for understanding mechaꢀ
nisms of drug resistance in schistosomes. Parasitology, 2013, 140,
1534–1546.
(8) Geary T. G.; Sakanari J., Caffrey C. R. Anthelmintic drug disꢀ
covery: into the future, J Parasitol. 2015, 10, 125–33.
(9) da Rocha Pitta, M. G.; da Rocha Pitta, M. G.; de Melo Rêgo,
M. J. B.; Galdino, S. L., The Evolution of Drugs on Schistosoma
Treatment: Looking to the Past to Improve the Future, MiniꢀReviews
in Medicinal Chemistry 2013, 13, 493ꢀ508.
(10) RojoꢀArreola L.; Long T.; Asarnow D.; Suzuki B. M.; Singh
R.; Caffrey C. R. Chemical and genetic validation of the statin drug
target to treat the helminth disease, schistosomiasis. PLoS ONE,
2014, 9, e87594.
(11) Fonseca, N. C.; da Cruz, L. F.; da Silva Villela, F.; do Nasciꢀ
mento Pereira, G. A.; de SiqueiraꢀNeto, J. L.; Kellar, D., et al. Synꢀ
thesis of a SugarꢀBased Thiosemicarbazone Series and Structureꢀ
Activity Relationship versus the Parasite Cysteine Proteases
Rhodesain, Cruzain, and Schistosoma mansoni Cathepsin B1, Antimiꢀ
crob Agents Chemother. 2015, 59, 2666–2677.
(12) Morel M.; Vanderstraete, M.; Cailliau, K,; Lescuyer, A.;
Lancelot, J.; Dissous, C. Compound library screening identified
Akt/PKB kinase pathway inhibitors as potential key molecules for the
development of new chemotherapeutics against schistosomiasis., Int J
Parasitol Drugs Drug Resist. 2014, 4, 256–66.
(13) Patel, G.; Roncal, N. E.; Lee, P. J.; Leed, S. E.; Erath, J.; Roꢀ
driguez, A.; et al. Repurposing human Aurora kinase inhibitors as
leads for antiꢀprotozoan drug discovery. MedChemComm. 2014, 5,
655–658.
(14) Long, T.; Neitz, R. J.; Beasley, R.; Kalyanaraman, C.; Suzuki,
B. M.; Jacobson, M. P.; et al. StructureꢀBioactivity Relationship for
Benzimidazole Thiophene Inhibitors of PoloꢀLike Kinase 1 (PLK1), a
Potential Drug Target in Schistosoma mansoni. PLoS Negl Trop Dis.
2016, 10, e0004356.
(15) Neves, B. J.; Andrade, C. H; Cravo, P. V., Natural products as
leads in schistosome drug discovery. Molecules, 2015, 20, 1872–903.
(16) da Silva, V. B. R.; Campos, B. R. K.; de Oliveira, J. F.; Deꢀ
cout, JꢀL.; do Carmo Alves de Lima, M. Medicinal chemistry of anꢀ
tiSchistosomal drugs: Praziquantel and Oxamniquine. Bioorg. Med.
Chem. 2017, 25, 3259ꢀ3277.
(17) Pellegrino, J; Pereira, L. H.; Mello, R. T.; Katz, N., Activity of
Some Tetrahydroꢀ and Pyrazinoquinolines against Early Developing
Forms of Schistosoma mansoni. J. of Parasitology. 1974, 60, 723ꢀ
725.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
(29) RuizꢀCastillo, P.; Buchwald, S. L., Applications of Palladiumꢀ
Catalyzed C–N CrossꢀCoupling Reactions. Chem. Rev. 2016, 116,
12564–12649.
(30) Ludovic, J.; Rouden, J.; Maddaluno, J.; Lasne, M.C. Palladiꢀ
umꢀMediated Arylations of 3ꢀAminopiperidines and 3ꢀ
Aminopyrrolidines, J. Org. Chem. 2004, 69, 8893ꢀ8902.
(31) Evans, E. F.; Lewis, N. J.; Kapfer, I.; Macdonald, G.; Taylor,
R. J. K., NꢀtertꢀButoxycarbonyl (BOC) Deprotection Using Boron
Trifluoride Etherate. Syn. Comm. 1997, 27, 1819ꢀ1825.
(32) Gillis, E. P.; Eastman, K. J.; Hill, M. D.; Donnelly, D. J.;
Meanwell, N. A., Applications of Fluorine in Medicinal Chemistry. J.
Med. Chem., 2015, 58, 8315ꢀ8359.
(33) Property calculations and data were archived and analyzed usꢀ
ing the CDD Vault from Collaborative Drug Discovery (Burlingame,
mAxon's JChem Base was used for structure searching, chemical
database access and management, and chemical property calculations.
ChemAxon (http://www.chemaxon.com).
(34) The evidence for preferentially binding and sulfur transfer of
enantiomers of compound 3 was observed in previous work. See refꢀ
erences 5 and 6.
(35) Terwilliger, T. C.; GrosseꢀKunstleve, R. W.; Afonine, P. V.;
Moriarty, N. W.; Adams, P. D.; Read, R. J.; Zwart, P. H.; Hung, L.
W. Iterativeꢀbuild OMIT maps: map improvement by iterative model
building and refinement without model bias. Acta Cryst. 2008, D64,
515ꢀ524.
(36) Taylor, A. B.; PicaꢀMattoccia, L.; Polcaro, C. M.; Donati, E.;
Cao, X.; Basso, A.; Guidi, A.; Rugel, A. R.; Holloway, S. P.; Anderꢀ
son, T. J.; Hart, P. J.; Cioli, D.; LoVerde, P. T. Structural and funcꢀ
tional characterization of the enantiomers of the antiSchistosomal
drug oxamniquine. PloS Negl. Trop. Dis. 2015, 9, e0004132.
(18) Filho, R. P.; Souza Menezes, C. M.; de, Pinto, P. L. S.; Paula,
G. A.; Brandt, C. A.; Silveira, M. A. B. Design, synthesis, and in vivo
ACS Paragon Plus Environment